Jay M. Edelberg

4.9k total citations · 1 hit paper
46 papers, 2.3k citations indexed

About

Jay M. Edelberg is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Jay M. Edelberg has authored 46 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cardiology and Cardiovascular Medicine, 16 papers in Molecular Biology and 15 papers in Surgery. Recurrent topics in Jay M. Edelberg's work include Cardiomyopathy and Myosin Studies (11 papers), Cardiovascular Function and Risk Factors (8 papers) and Angiogenesis and VEGF in Cancer (8 papers). Jay M. Edelberg is often cited by papers focused on Cardiomyopathy and Myosin Studies (11 papers), Cardiovascular Function and Risk Factors (8 papers) and Angiogenesis and VEGF in Cancer (8 papers). Jay M. Edelberg collaborates with scholars based in United States, United Kingdom and France. Jay M. Edelberg's co-authors include Robert Rosenberg, William C. Aird, Victoria L. T. Ballard, May J. Reed, Bernardo L. Trigatti, Kaori Sato, Mark J. Post, Mark D. Schrenzel, Monty Krieger and Michael Simons and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Investigation.

In The Last Decade

Jay M. Edelberg

46 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy

2022 183 citations Milind Y. Desai, Anjali Owens et al. Journal of the American College of Cardiology profile →

Peers

Countries citing papers authored by Jay M. Edelberg

Since Specialization

Citations

This map shows the geographic impact of Jay M. Edelberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay M. Edelberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay M. Edelberg more than expected).

Fields of papers citing papers by Jay M. Edelberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay M. Edelberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay M. Edelberg. The network helps show where Jay M. Edelberg may publish in the future.

Co-authorship network of co-authors of Jay M. Edelberg

This figure shows the co-authorship network connecting the top 25 collaborators of Jay M. Edelberg. A scholar is included among the top collaborators of Jay M. Edelberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay M. Edelberg. Jay M. Edelberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption 2023 ·JAMA Cardiology ·Matthew T. Wheeler, Iacopo Olivotto, Perry Elliott, Sara Saberi, Anjali Owens, Matthew J. Maurer, Ahmad Masri, Amy J. Sehnert, Jay M. Edelberg, (unknown), Victoria Florea, Rajeev Malhotra, Andrew Wang, Artur Oręziak, Jonathan Myers	31
2	THE EFFECT OF MAVACAMTEN ON CARDIOPULMONARY EXERCISE TESTING PERFORMANCE OF PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN EXPLORER-HCM 2022 ·Journal of the American College of Cardiology ·(unknown), Iacopo Olivotto, Perry Elliott, Sara Saberi, Anjali Owens, Mathew S. Maurer, Ahmad Masri, Amy J. Sehnert, Jay M. Edelberg, Wanying Li, Victoria Florea, Rajeev Malhotra, Andrew Wang, Artur Oręziak, Daniel Jacoby, Jonathan Myers	2
3	The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review 2022 ·American Journal of Cardiovascular Drugs ·Jay M. Edelberg, Amy J. Sehnert, Matthew E. Mealiffe, Carlos del Río, Robert S. McDowell	22
4	Effect of Beta-Blocker Therapy on the Response to Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy 2022 ·European Journal of Heart Failure ·Matthew T. Wheeler, Daniel Jacoby, Perry Elliott, Sara Saberi, Sheila M. Hegde, Neal K. Lakdawala, Jonathan Myers, Amy J. Sehnert, Jay M. Edelberg, Wanying Li, Iacopo Olivotto	26
5	Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States 2021 ·Journal of Medical Economics ·Sneha S. Jain, (unknown), Jipan Xie, (unknown), Jennifer Fine, Jay M. Edelberg, Wei Gao, John A. Spertus, David J. Cohen	24
6	Abstract 9685: Long-Term Efficacy and Safety of Mavacamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy: Interim Results from the MAVERICK-LTE Cohort of the MAVA-LTE Study 2021 ·Circulation ·Anjali Owens, Mark V. Sherrid, Timothy C. Wong, Richard G. Bach, Omar Wever‐Pinzon, Marzia Rigolli, Ganesh Balaratnam, (unknown), Matthew E. Mealiffe, Jay M. Edelberg, Neal K. Lakdawala, Ahmad Masri, Andrew Wang	8
7	Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy 2021 ·American Heart Journal ·Milind Y. Desai, Kathy Wolski, Anjali Owens, Srihari S. Naidu, Jeffrey B. Geske, Nicholas G. Smedira, Hartzell V. Schaff, Kathy Lampl, Ellen McErlean, Christina Sewell, David Zhang, Jay M. Edelberg, Amy J. Sehnert, Steven E. Nissen	38
8	Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference 2017 ·Cardiovascular Drugs and Therapy ·Thomas J. Povsic, Robert C. Scott, Kenneth W. Mahaffey, Robert O. Blaustein, Jay M. Edelberg, Martin Lefkowitz, Scott D. Solomon, Jonathan C. Fox, Kevin E. Healy, Aarif Y. Khakoo, Douglas W. Losordo, Fady I. Malik, Brett P. Monia, Rusty L. Montgomery, Jeffrey S. Riesmeyer, Gregory G. Schwartz, Steven L. Zelenkofske, Joseph C. Wu, Scott M. Wasserman, Matthew T. Roe	8
9	Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program) 2016 ·The American Journal of Cardiology ·Daniel Gaudet, Gerald F. Watts, Jennifer G. Robinson, Pascal Minini, William J. Sasiela, Jay M. Edelberg, Michael J. Louie, Frederick J. Raal	105
10	Targets for regulating angiogenesis in the ageing endothelium 2007 ·Expert Opinion on Therapeutic Targets ·Victoria L. T. Ballard, Jay M. Edelberg	13
11	Endothelial Precursor Cells 2007 ·Stem Cell Reviews and Reports ·May J. Reed, (unknown), (unknown), Jay M. Edelberg	11
12	Growth factor-mediated reversal of senescent dysfunction of ischemia-induced cardioprotection 2005 ·American Journal of Physiology-Heart and Circulatory Physiology ·Jingang Zheng, Andrew I. Chin, Inga Duignan, (unknown), Mun K. Hong, Jay M. Edelberg	16
13	A potent opiate agonist protects against myocardial stunning during myocardial ischemia and reperfusion in rats 2005 ·Coronary Artery Disease ·(unknown), Jinho Shin, (unknown), Hyun Joong Kim, (unknown), Jay M. Edelberg, S. Chiu Wong, Hazel H. Szeto, Mun K. Hong	25
14	Platelet-derived growth factor improves cardiac function in a rodent myocardial infarction model 2004 ·Coronary Artery Disease ·Jingang Zheng, Jinho Shin, Munira Xaymardan, Andrew I. Chin, Inga Duignan, Mun K. Hong, Jay M. Edelberg	12
15	Genetically Engineered Biologically Based Hemostatic Bioassay 2003 ·Annals of Biomedical Engineering ·Lilong Tang, David J. Christini, Jay M. Edelberg	3
16	Translation of PDGF Cardioprotective Pathways 2003 ·Cardiovascular Toxicology ·Jay M. Edelberg, Dongqing Cai, Munira Xaymardan	12
17	Aging‐Associated Changes in Vascular Activity: A Potential Link to Geriatric Cardiovascular Disease 2001 ·The American Journal of Geriatric Cardiology ·Jonathan W. Weinsaft, Jay M. Edelberg	51
18	PDGF mediates cardiac microvascular communication. 1998 ·Journal of Clinical Investigation ·Jay M. Edelberg, William C. Aird, Wei Wu, Helen Rayburn, Wilfred Mamuya, Mark Mercola, Robert Rosenberg	88
19	Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. 1998 ·Journal of Clinical Investigation ·Jay M. Edelberg, William C. Aird, Robert Rosenberg	88
20	Purification of Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase 1996 ·Journal of Biological Chemistry ·Jian Liu, Nicholas W. Shworak, Linda M.S. Fritze, Jay M. Edelberg, Robert Rosenberg	97

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact